Jörn Aldag resigns as CEO of Evotec AG
Evotec AG announced that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will be effective as of December 31, 2008. Dr Mario Polywka, Chief Operating Officer, and Dr Klaus Maleck, Chief Financial Officer, will jointly lead the Company until a permanent successor is announced.
Dr Flemming Ornskov, Chairman of the Supervisory Board of Evotec, said: "During his eleven-year tenure at Evotec Jörn Aldag played a pivotal role in the transformation of Evotec from a technology provider to an integrated, CNS-focused biopharmaceutical company. Today the Company has a very strong financial position and a deep preclinical and clinical pipeline of CNS drug candidates that provide a strong basis for future success. On behalf of the Evotec Supervisory Board, I would like to thank Jörn Aldag for his effective and very successful leadership of the Company and we wish him ongoing success for his future endeavors."
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
